

Key facts and findings



What did we find?

No effective framework for dealing with critical shortages.

The European Medicines Agency provided important coordination to help reduce the impact of shortages.

Fragmentation of the EU medicines market hinders the free flow and availability of products, and results in unequal access to them.

Efforts to address root causes (including supply chain vulnerabilities) are still at an early stage.